BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Fulvestrant: trial readouts and FDA decisions

6 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 7 readout(s) in the last 180 days and 1 FDA event(s) in the last 12 months. Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis Pharmaceuticals, InventisBio Co., Ltd, Phoenix Molecular Designs, Pfizer, Hoffmann-La Roche, AstraZeneca, Olema Oncology, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P3InventisBio Co., LtdNCT06954961 A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast CancerBreast Cancerrecruiting640
2026-12 est.P1/P2Phoenix Molecular DesignsNCT04115306 Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast CancerMetastatic Breast Canceractive not recruiting61
2026-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerMetastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignanciesrecruiting154
2026-12-31 est.P2Pfizer PFENCT04553133 PF-07104091 as a Single Agent and in Combination TherapySmall Cell Lung Cancer; Ovarian Cancer; Breast Canceractive not recruiting157
2027-01-28 est.P3Novartis Pharmaceuticals NVSNCT05038735 Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After TreatmBreast Canceractive not recruiting210
2027-01-29 est.P2Novartis Pharmaceuticals NVSNCT04544189 Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women WitBreast Neoplasmsactive not recruiting69

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-04-13Complete response lettercomplete responseEagle Pharmaceuticals, Inc. EXPFulvestrantCRL 2026-04-13: Eagle Pharmaceuticals, Inc. NDA 220045 (Fulvestrant Injection)

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P3Hoffmann-La RocheNCT05646862 A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-NegatiBreast Cancerrecruiting420
2026-10-31 est.P3AstraZeneca AZNNCT06635447 Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsBreast Canceractive not recruiting293
2026-10-31 est.P3Olema Oncology, Inc. OLMANCT06016738 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerBreast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negactive not recruiting510
2026-10 est.P3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06929325 Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 InhibiHR+/HER2- Advanced/Metastatic Breast Cancernot yet recruiting312
2026-08 est.P1/P2Treadwell Therapeutics, IncNCT05251714 CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast CancerAdvanced Solid Tumor; Breast Canceractive not recruiting44
2026-06-30 est.P3Celcuity Inc CELCNCT05501886 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (Breast Canceractive not recruiting701
2026-06 est.P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06702618 Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast CancerBreast Canceractive not recruiting33

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.